http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0783309-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5fa84b996b313a1066cb6ec8c481a8d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 |
| filingDate | 1995-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98b39255c8e07bc62b12ea7766cf1b8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d27b052149b5892fa9cc87f7ed258718 |
| publicationDate | 1997-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0783309-A2 |
| titleOfInvention | Use of a corticosteroid to reduce the adverse effects of a perfluorochemical emulsion |
| abstract | This invention is directed to a method of attenuating or preventing the adverse side-effects of a perfluorochemical (PFC) emulsion on the hemostatic system and serum chemistry of an animal. The method includes intravenously administering a corticosteroid to an animal prior to intravenous administration of a PFC emulsion, in an amount sufficient to improve the adverse effects of the PFC upon the hemostatic system and serum triglyceride/enzyme levels of the animal. After administration of the corticosteroid, the PFC emulsion is administered intravenously. Preferably, the corticosteroid is dexamethasone, and the PFC is perfluorodichlorooctane. |
| priorityDate | 1994-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.